Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma Clinical Trial

Official title:

A Single Dose, Randomized, Open-label, 3-Way Cross-over Clinical Pharmacology Study, to Evaluate the Systemic Exposure of BDP, Beclomethasone 17-monoproprionate, Formoterol Fumarate, and Glycopyrronium Bromide, After Inhalation of the Fixed Combination BDP/FF/GB HFA pMDI (CHF 5993) at Two Different Strengths and of BDP Hydrofluoroalkane (HFA), in Healthy Volunteers.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05898984
• Other study ID #: CLI-05993AB8-01
• Status: Recruiting
• Phase: Phase 1
• Start date: April 24, 2023
• Est. completion date: August 3, 2023

Study information

• Verified date: June 2023
• Source: Chiesi Farmaceutici S.p.A.
• Contact: Chiesi clinical Trial Info
• Phone: +3950212791
• Email: clinicaltrials_info[@]chiesi.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is being conducted to compare the pharmacokinetic (PK) of BDP (and its main active metabolite B17MP), FF, and GB between CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI and CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI (pressurized Metered Dose Inhaler), to assess the proportionality of systemic exposure to BDP and B17MP (17-Monoproprionate), and the systemic exposure to FF and GB with increasing doses of BDP.

The study includes a QVAR REDIHALER® arm too.

Description:

The main purpose of this study is to evaluate the systemic exposure to B17MP, FF, and GB as the area under the concentration-time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) and maximum plasma concentration (Cmax) across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 μg and 100/6/12.5 μg).

The secondary purposes of the study are:

1. To evaluate the pharmacokinetic profile of BDP and additional pharmacokinetic parameters of B17MP, FF, and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 μg and 100/6/12.5 μg);

2. To compare the exposure to BDP and B17MP between the high dose BDP/FF/GB (total daily dose [TDD]: 800/24/50 µg) and the highest US-approved dose of QVAR (TDD 800 µg).

3. generate additional safety and tolerability information of the two CHF 5993 pDMI strengths, after a single dose.

Participation in the study will last for a maximum of 70 days for each subject (starting from randomization).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 69
• Est. completion date: August 3, 2023
• Est. primary completion date: August 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subject's written informed consent ;

• 18-55 years of age;

• Ability to understand the study procedures, the risks involved and ability to be trained to correctly use the inhalers.

• Body mass index of 19.0 to 30.0 kg/m2 (extremes inclusive), and body weight =50.0 kg;

• Non- or ex-smokers who smoked <5 pack-years and stopped smoking >1 year prior to screening;

• Good physical and mental status, determined based on the medical history and a general clinical examination;

• Vital signs within normal limits at screening: diastolic blood pressure (DBP) 40 to 90 mmHg, systolic blood pressure (SBP) 90 to 140 mmHg

• 12-Lead digitised electrocardiogram (ECG) in triplicate considered as normal (40 = heart rate [HR] =110 beats per minute, 120 milliseconds [ms] = PR interval [PR] =220 ms [PR =120 ms without a delta wave may be acceptable], QRS interval [QRS] =120 ms, and Fridericia corrected QT interval [QTcF] =450 ms for males and QTcF =470 ms for females).

• Lung function measurements within normal limits at screening: forced expiratory volume in the first second (FEV1) equal to or more than 80% of predicted for the subject's normal value according to the Global Lung Function Initiative, European Respiratory Society Task Force Lung Function Reference Values and FEV1/forced vital capacity ratio >0.70.

• Female subjects of non-chid bearing potential or females of childbearing potential with a negative pregnancy test and acceptable contraceptive methods.

Exclusion Criteria:

• Participation in another clinical study with an investigational drug in the 30 days or five half-lives of that investigational drug (whichever is longer) preceding the administration of the study treatment; longer and more appropriate time could be considered by the Investigator based on the terminal half-life (t1/2) and/or long-term toxicity of the previous investigational drug;

• Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic or psychiatric disorders that may interfere with successful completion of this protocol according to the Investigator's judgment;

• Subjects with history of breathing problems (i.e. history of asthma including childhood asthma);

• Positive urine test for cotinine.

• Intake of non-permitted concomitant medications in the predefined period prior to screening, or prior to randomisation or the subject is expected to take non-permitted concomitant medications during the study;

• Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or prior to randomisation;

• Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the study;

• Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would prevent use of anticholinergics;

• For females only: pregnant or lactating women.

• Subjects receiving treatment with any drug known to have a well defined potential for hepatotoxicity.

• Subjects using e-cigarettes within 6 months before screening.

Other Inclusion/exclusion criteria as defined by the protocol.

Related Conditions & MeSH terms

• Asthma
• Respiratory Aspiration

Intervention

Drug:
• Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI
CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [200 µg], FF [6 µg] and GB [12.5 µg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a total daily dose (TDD) of BDP/FF/GB: 800/24/50 µg. Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI with HFA 134a propellant (fixed combination of BDP [100 µg], FF [6 µg] and GB [12.5 µg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg. Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 µg): pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).
• Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI
with HFA 134a propellant (fixed combination of BDP [100 µg], FF [6 µg] and GB [12.5 µg] via pMDI): 4 inhalations alternated with 4 inhalations of CHF 5993 placebo, corresponding to 8 inhalations in total and giving a TDD of BDP/FF/GB: 400/24/50 µg
• Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 µg)
pressurised, breath-actuated, metered dose aerosol with a dose counter): 8 inhalations (TDD of BDP: 640 µg ex-actuator, 800 µg ex valve).

Locations

Country	Name	City	State
Belgium	SGS Belgium NV - Clinical Pharmacology Unit	Edegem	Antwerpen

Sponsors (2)

Lead Sponsor	Collaborator
Chiesi Farmaceutici S.p.A.	SGS S.A.

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	systemic exposure ( area under the concentration time curve from zero to time) to beclomethasone 17 monopropionate (B17MP), FF and GB	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the systemic exposure to beclomethasone 17 monopropionate (B17MP), FF and GB as area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg).	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Primary	systemic exposure (maximum plasma concentration (Cmax) ) to beclomethasone 17 monopropionate (B17MP), FF and GB	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the systemic exposure to beclomethasone 17 monopropionate (B17MP), FF and GB as maximum plasma concentration (Cmax) across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg).	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Area under the concentration-time curve from zero to infinity (AUC0-8) of B17MP, FF and GB across two different dose strengths of CHF 5993.	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the area under the concentration-time curve from zero to infinity (AUC0-8) of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Time to Cmax (t max) of B17MP, FF and GB across two different dose strengths of CHF 5993.	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the Time to Cmax (t max) of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Time to t1/2 of B17MP, FF and GB across two different dose strengths of CHF 5993.	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the Time to t1/2 of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) of BDP across two different dose strengths of CHF 5993	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Time to Cmax (t max) of BDP across two different dose strengths of CHF 5993	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To Time to Cmax (t max) of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	t max of BDP across two different dose strengths of CHF 5993	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI: To evaluate the tmax of B17MP, FF and GB across two different dose strengths of CHF 5993 BDP/FF/GB (200/6/12.5 µg and 100/6/12.5 µg);	From pre-dose to 24 hours post dose for BDP/B17MP and from pre-dose to 72hours post dose for FF and GB
Secondary	Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) of BDP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg)	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to BDP as Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) for B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) of B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to B17MP as Area under the concentration time curve from zero to time 't' where t is the last quantifiable time point (AUC0-t) for B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	maximum plasma concentration (Cmax) of BDP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to BDP as maximum plasma concentration (Cmax) for B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	maximum plasma concentration (Cmax) of B17MPafter a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to B17MP as maximum plasma concentration (Cmax) for B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	t max of BDP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to BDP as t max after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	t max of BDP of B17MPafter a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to B17MP as t max after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	Area under the concentration-time curve from zero to infinity (AUC0-8) of B17MPafter a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to B17MP as Area under the concentration-time curve from zero to infinity (AUC0-8) after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	Time to t1/2 of B17MPafter a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI vs. BDP HFA (QVAR REDIHALER®, BDP 80 µg): To compare the systemic exposure to B17MP as Time to t1/2 of B17MP after a single inhaled dose of CHF 5993 BDP/FF/GB 200/6/12.5 µg and of BDP HFA (QVAR REDIHALER®, BDP 80 µg);	From pre-dose to 24 hours post dose
Secondary	Incidence of Adverse events	Number and percentage of subject with at least one event and number of treatment-emergent events.	through study completion, an average of 90 days, screening phase inclusive
Secondary	Incidence of study drugs reactions	Number and percentage of subject with at least one event and number of treatment-emergent events.	through study completion, an average of 90 days, screening phase inclusive
Secondary	Change of systolic and diastolic Blood pressure	The number and percentage of subjects with QTcF in the following intervals will be presented at each post-dose time point and at any post-dose time point by treatment: • Change from pre-dose >20 mmHg for SBP; Change from pre-dose >10 mmHg for DBP.	from pre-dose to 24hours post dose
Secondary	12-lead ECG	The number and percentage of subjects with abnormal actual QTcF (Fridericia-correctedQT Interval).	From Pre-dose to 75 minutes post dose
Secondary	12-lead ECG	The number and percentage of subjects with abnormal change from the baseline of QTcF	From Pre-dose to 75 minutes post dose
Secondary	Number of participants with abnormal laboratory test results	Clinical chemistry,Fasting serum glucose;Haematology parameters will be evaluated. For continuous laboratory parameters, the laboratory values and the change from baseline will be summarised at each visit by treatment sequence using descriptive statistics. For categorical laboratory parameters, a frequency table of results will be produced at each visit by treatment sequence.	through study completion, an average of 90 days, screening phase inclusive
Secondary	body temperature abnormal values	For continuous laboratory parameters, the laboratory values and the change from baseline will be summarised at each visit by treatment sequence using descriptive statistics.	through study completion, an average of 90 days, screening phase inclusive
Secondary	Number of participants with abnormal results of physical examinations	For continuous laboratory parameters, the laboratory values and the change from baseline will be summarised at each visit by treatment sequence using descriptive statistics.	through study completion, an average of 90 days, screening phase inclusive